BLU-5937 for Refractory Chronic Cough: 24-Week Test in Adults (China Extension)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, randomized, double-blind, placebo-controlled trial comparing BLU-5937 to placebo in adults with chronic cough that has not improved with other treatments. Participants are assigned to BLU-5937 or placebo for 24 weeks, with the main outcome being change in 24-hour cough frequency. The trial follows a parallel-arm design to evaluate efficacy and safety in the target population. The China extension expands sites to additional investigational locations under the lead sponsor, GlaxoSmithKline.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Capable of giving signed informed consent
* Refractory chronic cough (including unexplained chronic cough) for at least one year

  * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose

Exclusion Criteria:

* Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
* Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment
* Respiratory tract infection within 4 weeks before screening
* Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening
* History of malignancy in the last 5 years
* History of alcohol or drug abuse within the last 3 years
* Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus.
* Previous participation in a BLU-5937 trial

Where it's running

• GSK Investigational Site
  Leshan, Sichuan, China Recruiting
• GSK Investigational Site
  Beijing, China Recruiting
• GSK Investigational Site
  Changsha, China Recruiting
• GSK Investigational Site
  Chengdu, China Recruiting
• GSK Investigational Site
  Chengdu, China Recruiting
• GSK Investigational Site
  Chongqing, China Recruiting

Study contacts

• Study coordinator: US GSK Clinical Trials Call Center
• Email: GSKClinicalSupportHD@gsk.com
• Phone: 877-379-3718

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nalbuphine ER for chronic cough in people with RCC

  This study tests whether extended-release nalbuphine helps people with unexplained, long-standing cough that hasn’t improved with other treatments.

  Recruiting at 21 sites Phase 2 Trevi Therapeutics · Kelowna, British Columbia and 20 other locations · NCT07671924

• Cough Management app for refractory or unexplained chronic cough

  This trial will see if using a smartphone Cough Management program plus a smartwatch for four weeks lowers coughing and improves quality of life in adults 21–80 with refractory or unexplained chronic cough.

  Recruiting Hyfe Inc · Wilmington, Delaware · NCT07070895

• Behavioral Cough Suppression Therapy with or without an inhaled aid for refractory chronic cough

  This study tests whether adding an inhaled substance to behavioral cough suppression helps people with persistent chronic cough see if it works better than behavior therapy alone.

  Recruiting at 2 sites Phase 2 University of Montana · Aurora, Colorado and 2 other locations · NCT06960759

• Testing Duloxetine and Amitriptyline for Chronic Cough Relief

  This study is testing if two medications, Duloxetine and Amitriptyline, can help people with a stubborn chronic cough feel better.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT05110144

• Magnesium spray for refractory or unexplained chronic cough in adults

  A small study tests SC0032, a magnesium salt spray you spray in your mouth, to see if it reduces coughing compared with a placebo in adults with RCC or UCC.

  Recruiting at 3 sites Phase 2 Sensory Cloud, Inc. · Belfast and 2 other locations · NCT07690059

• Chronic Cough and Airway Remodelling in Refractory Cough Patients

  This study tests whether long-lasting chronic cough damages and remodels the airways in adults who have had cough for over a year and have not responded to prior treatments.

  Recruiting at 4 sites Medical University of Warsaw · Warsaw, Masovian Voivodeship and 3 other locations · NCT07659860

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.